MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 20...(ospective investors arecautioned not to ...)

Date:3/4/2008

ospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. MiddleBrook undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.

MIDDLEBROOK PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Product sales $2,858,573 $1,243,847 $10,456,700 $4,810,410

Costs and expenses:

Cost of product

sales 712,311 381,836 2,576,954 899,601

Research and

development 3,472,544 6,273,581 21,957,708 25,973,844

Selling, general

and

administrative 5,569,764 8,287,656 26,043,711 21,288,968

Total expenses 9,754,619 14,943,073 50,578,373 48,162,413

Loss from

operations (6,896,046) (13,699,226) (40,121,673) (43,352,003)

Interest income 61,587 147,764 543,442 895,685

Interest expense (55,352) (218,633) (584,276) (510,651)

Early extinguishment

of debt (224,048) - (224,048) -

Warrant expense (2,100,000) - (2,100,000) -

Other income - - 75,000 976,815

Loss including

noncontrolling

interest (9,213,859) (13,770,095) (42,411,555) (41,990,154)

Loss attributable

to noncontrolling

interest 162,189
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences